CYT — Cyteir Therapeutics Share Price
Last trade - 00:00- $111.95m
- -$17.29m
- 44
- 35
- 77
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.9 | ||
| Price to Tang. Book | 0.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.34% | ||
| Return on Equity | -23.8% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.01 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
Directors
- Joseph Zakrzewski NEC
- Markus Renschler PRE (58)
- Paul Secrist CSO (55)
- David Gaiero VFN (43)
- Jean-Marc Lapierre VPR
- Barbara Wan VRD
- Andrew Gengos OTH (56)
- Jeffrey Humphrey DRC
- John Thero DRC (61)
- Racquel Bracken IND (38)
- Jean George IND (63)
- Susan Molineaux IND (67)
- Janwillem Naesens IND (38)
- Timothy Romberger IND (49)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- June 4th, 2012
- Public Since
- June 18th, 2021
- No. of Shareholders
- 30
- No. of Employees
- 46
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 35,998,068
- Address
- P.O. Box 80084, STONEHAM, 02180
- Web
- https://cyteir.com/
- Phone
- +1 8572854140
- Auditors
- Ernst & Young LLP
Upcoming Events for CYT
Similar to CYT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:06 UTC, shares in Cyteir Therapeutics are trading at $3.11. This share price information is delayed by 15 minutes.
Shares in Cyteir Therapeutics last closed at $3.11 and the price had moved by +86.23% over the past 365 days. In terms of relative price strength the Cyteir Therapeutics share price has outperformed the S&P500 Index by +40.35% over the past year.
The overall consensus recommendation for Cyteir Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCyteir Therapeutics does not currently pay a dividend.
Cyteir Therapeutics does not currently pay a dividend.
Cyteir Therapeutics does not currently pay a dividend.
To buy shares in Cyteir Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.11, shares in Cyteir Therapeutics had a market capitalisation of $111.95m.
Here are the trading details for Cyteir Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CYT
Based on an overall assessment of its quality, value and momentum Cyteir Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cyteir Therapeutics is $3.00. That is 3.54% below the last closing price of $3.11.
Analysts covering Cyteir Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.08 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyteir Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -0.95%.
As of the last closing price of $3.11, shares in Cyteir Therapeutics were trading +9.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cyteir Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cyteir Therapeutics' management team is headed by:
- Joseph Zakrzewski - NEC
- Markus Renschler - PRE
- Paul Secrist - CSO
- David Gaiero - VFN
- Jean-Marc Lapierre - VPR
- Barbara Wan - VRD
- Andrew Gengos - OTH
- Jeffrey Humphrey - DRC
- John Thero - DRC
- Racquel Bracken - IND
- Jean George - IND
- Susan Molineaux - IND
- Janwillem Naesens - IND
- Timothy Romberger - IND